Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aticaprant - Johnson & Johnson Innovative Medicine

Next Previous
X
Search
Drug Profile

Aticaprant - Johnson & Johnson Innovative Medicine

Alternative Names: AVTX-501; CERC 501; JNJ-3964; JNJ-67953964; JNJ-67953964-AAA; LY-2456302

Latest Information Update: 16 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Avalo Therapeutics; Eli Lilly and Company; Johnson & Johnson Innovative Medicine
  • Class Antidepressants; Benzamides; Benzene derivatives; Drug withdrawal therapies; Fluorinated hydrocarbons; Pyrrolidines; Smoking cessation therapies
  • Mechanism of Action Opioid kappa receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Major depressive disorder
  • Discontinued Alcoholism; Cocaine-related disorders; Smoking withdrawal

Most Recent Events

  • 13 Dec 2024 Johnson & Johnson Innovative Medicine completes a phase III VENTURA-2 trial in Major depressive disorder (Adjunctive treatment) in US, Argentina, Brazil, Bulgaria, China, Czech Republic, France, South Korea, Poland, Slovakia, South Africa, Taiwan (PO) (NCT05550532)
  • 19 Sep 2024 Janssen Research & Development initiates a phase III VENTURA-5 trial for Major depressive disorder (Adjunctive treatment) in USA (PO, Tablet) (NCT06635135) (EudraCT 2024-511057-22-00)
  • 26 Jun 2024 Janssen Research & Development initiates a phase III VENTURA-7 trial for Major depressive disorder (Adjunctive treatment) in USA (PO, Tablet) (NCT06514742) (EudraCT2024-511557-21-00)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top